title: Individual residual symptoms and functional impairment in patients with depression.
abstract: The aim of treatment of depression is remission of symptoms and functioning. Although there is a relationship between remission of symptoms and remission of functioning, it is not known how individual residual symptoms are related to functioning. Here we report a post-hoc analysis of two studies which treated depressed patients with duloxetine in an open fashion for 10-12 weeks. We evaluated the association of individual residual symptoms and functional impairment in patients who remitted or partially remitted after acute treatment. Logistic regression was used to investigate residual symptoms associated with functional impairment at endpoint. Our results suggest that in partial remitters, the only residual symptom associated with a reduction in the risk of having impaired function was the resolution of painful physical symptoms (PPS). In patients who remitted, the presence of residual core mood symptoms (CMS), particularly in patients without any anxiety, predicted impaired functioning. The resolution of PPS in the presence of residual CMS was associated with less risk of impaired functioning. Our results contribute to understand better the role of specific residual symptoms on functional impairment. To achieve normal functioning, intervention on specific residual symptoms is recommended.
authors.affiliation: Department of Clinical Research Lilly, S.A. Avenida de la Industria 30, 28108 Alcobendas, Spain; Autonomous University of Barcelona, Spain. Electronic address: romera_irene@lilly.com.
authors.forename: Irene
authors.initials: I
authors.lastname: Romera
authors.affiliation: Department of Psychiatry, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona/CIBERSAM, Barcelona, Spain.
authors.forename: Víctor
authors.initials: V
authors.lastname: Pérez
authors.affiliation: Eli Lilly UK, Windlesham, UK.
authors.forename: Deborah
authors.initials: D
authors.lastname: Quail
authors.affiliation: Eli Lilly, Global Statistical Sciences, Bad Homburg, Germany.
authors.forename: Lovisa
authors.initials: L
authors.lastname: Berggren
authors.affiliation: Eli Lilly UK, Basingstoke, UK.
authors.forename: Alan
authors.initials: A
authors.lastname: Lenox-Smith
authors.affiliation: Universidad San Pablo CEU, Madrid, Spain.
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Gilaberte
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D003865:Major Depressive Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D012893:Sleep Wake Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
keywords: Functioning; Major depression disorder; Residual symptoms